Immix Biopharma (NASDAQ:IMMX) Stock Price Up 11.4% – What’s Next?

Immix Biopharma, Inc. (NASDAQ:IMMX)’s stock price was up 11.4% during trading on Tuesday . The stock traded as high as $11.25 and last traded at $11.6370. 953,418 shares were traded during mid-day trading, a decline of 16% from the average session volume of 1,133,501 shares. The stock had previously closed at $10.45.

Analysts Set New Price Targets

Several brokerages have recently issued reports on IMMX. Citigroup assumed coverage on Immix Biopharma in a research report on Thursday, June 18th. They set a “buy” rating for the company. Lifesci Capital initiated coverage on Immix Biopharma in a research note on Wednesday, June 17th. They set an “outperform” rating and a $19.00 target price on the stock. Wall Street Zen lowered Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Mizuho increased their price target on Immix Biopharma from $14.00 to $15.00 and gave the stock an “outperform” rating in a research note on Monday, March 30th. Finally, Citizens Jmp reissued a “market outperform” rating and set a $23.00 price target on shares of Immix Biopharma in a report on Friday, March 27th. Seven investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $20.67.

Immix Biopharma Stock Up 0.1%

The firm has a market cap of $599.05 million, a price-to-earnings ratio of -11.94 and a beta of 0.09. The stock’s 50 day moving average is $9.31 and its 200 day moving average is $8.19.

Immix Biopharma (NASDAQ:IMMX) last released its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.19) by $0.01. Analysts anticipate that Immix Biopharma, Inc. will post -0.69 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Immix Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of IMMX. Vanguard Group Inc. boosted its position in shares of Immix Biopharma by 4.5% during the 3rd quarter. Vanguard Group Inc. now owns 730,162 shares of the company’s stock valued at $1,526,000 after purchasing an additional 31,625 shares in the last quarter. Tocqueville Asset Management L.P. lifted its stake in Immix Biopharma by 37.4% during the third quarter. Tocqueville Asset Management L.P. now owns 40,250 shares of the company’s stock valued at $84,000 after purchasing an additional 10,950 shares during the last quarter. Imprint Wealth LLC acquired a new stake in Immix Biopharma during the third quarter valued at approximately $141,000. Citadel Advisors LLC acquired a new position in Immix Biopharma in the third quarter worth approximately $188,000. Finally, Susquehanna International Group LLP grew its position in Immix Biopharma by 78.8% in the third quarter. Susquehanna International Group LLP now owns 90,858 shares of the company’s stock worth $190,000 after buying an additional 40,032 shares during the last quarter. 11.26% of the stock is currently owned by institutional investors.

Immix Biopharma Company Profile

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.